Investing
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
Published:
Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day. Thus, choosing the right small-cap stocks can offer attractive short and long terms gains.
Such stocks, however, are more volatile, and thus, investors must select small-cap stocks very carefully. To give you an idea of the return you can make (or lose) in the short term, detailed below are the five best and worst performing small-cap stocks in September 2022.
We have used the September return data from finviz.com to rank the five best and worst performing small-cap stocks in September 2022. Here are the five best performing small-cap stocks in September 2022:
Founded in 1998 and headquartered in Austin, Texas, this company develops novel drugs and diagnostics for the treatment of Alzheimer’s disease. Cassava Sciences Inc (NASDAQ:SAVA) shares are down by almost 22% year to date and down almost 27% in the last year.
As of this writing, Cassava Sciences shares are trading above $34 with a 52-week range of $13.84 to $100.00, giving the company a market capitalization of more than $1.30 billion.
Founded in 2018 and headquartered in Encinitas, Calif., this company develops novel small molecule therapeutics for the treatment of autoimmune diseases. Ventyx Biosciences Inc (NASDAQ:VTYX) shares are up by over 34% year to date and up almost 27% in the last year.
As of this writing, Ventyx Biosciences shares are trading above $26 with a 52-week range of $9.50 to $41.29, giving the company a market cap of more than $1.40 billion.
Founded in 1996 and headquartered in Charlottesville, Va., this company discovers and develops medicines and diagnostics for Alzheimer’s disease. Acumen Pharmaceuticals Inc (NASDAQ:ABOS) shares are up by almost 11% year to date and down almost 49% in the last year.
As of this writing, Acumen Pharmaceuticals shares are trading above $7.40 with a 52-week range of $3.02 to $15.34, giving the company a market capitalization of more than $301 million.
Founded in 2008 and headquartered in Cambridge, Mass., this company develops new medicines that are unlikely to be found by usual drug discovery methods. Immuneering Corp (NASDAQ:IMRX) shares are down by almost 22% year to date and down over 52% in the last year.
As of this writing, Immuneering shares are trading above $12.60 with a 52-week range of $3.74 to $31.89, giving the company a market cap of more than $346 million.
Founded in 2017 and headquartered in South San Francisco, Calif., it is a cardio-metabolic nonalcoholic steatohepatitis company that develops medicines to restore metabolic balance and improve overall health. Akero Therapeutics Inc (NASDAQ:AKRO) shares are up by over 95% year to date and up over 97% in the last year.
As of this writing, Akero Therapeutics shares are trading above $41 with a 52-week range of $7.52 to $41.64, giving the company a market capitalization of more than $1.80 billion.
These are the five worst performing small-cap stocks in September 2022:
Founded in 1987 and headquartered in Gaithersburg, Md., this company discovers, develops and sells vaccines to prevent infectious diseases. Novavax, Inc. (NASDAQ:NVAX) shares are down by almost 88% year to date and down over 87% in the last year.
As of this writing, Novavax shares are trading above $17 with a 52-week range of $16.00 to $236.50, giving the company a market capitalization of more than $1.30 billion.
Founded in 1931 and headquartered in New York City, this company offers investment research. Value Line, Inc. (NASDAQ:VALU) shares are up by over 29% year to date and up over 93% in the last year.
As of this writing, Value Line shares are trading above $60 with a 52-week range of $31.02 to $118.40, giving the company a market cap of more than $570 million.
Founded in 2010 and headquartered in Los Angeles, CA, it is an interactive lifestyle and media platform that focuses on gaming and youth culture. FaZe Holdings Inc (NASDAQ:FAZE) shares are down by over 59% year to date and down almost 58% in one year.
As of this writing, FaZe Holdings shares are trading at above $4.10 with a 52-week range of $4.13 to $24.69, giving the company a market capitalization of more than $310 million.
Founded in 2014 and headquartered in San Francisco, this company operates a financial services platform to cater to the specific needs of the private market. Forge Global Holdings Inc (NYSE:FRGE) shares are down by almost 83% year to date and down over 83% in the last year.
As of this writing, Forge Global shares are trading above $1.60 with a 52-week range of $1.29 to $47.50, giving the company a market cap of more than $279 million.
Founded in 2012 and headquartered in San Francisco, this company develops and sells household, personal care, beauty, and other consumer products. Grove Collaborative Holdings Inc (NYSE:GROV) shares are down by almost 84% year to date and down over 83% in the last year.
As of this writing, Grove Collaborative shares are trading above $1.50 with a 52-week range of $1.3402 to $12.5033, giving the company a market capitalization of more than $280 million.
This article originally appeared on ValueWalk
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.